Wall Street Perspective on Boston Scientific Shares: Bullish or Bearish Trend Ahead?
Boston Scientific Corporation (BSX), a leading player in the medical devices industry, continues to garner positive sentiment from analysts. The mean price target of $124.53 from all analysts represents an 18.7% premium to BSX's current price levels.
The current analyst consensus for BSX is generally positive, with a "Buy" rating maintained by firms such as Truist Securities. The average analyst price target is around $119 to $125, with some variation among analysts. Notably, Truist Securities recently increased its price target from $120 to $125, following BSX's strong quarter with broad-based earnings beats and expected continued momentum in the second half of 2025.
Jayson Bedford, an analyst from Raymond James Financial, Inc. (RJF), maintains a "Buy" rating on BSX, with a price target of $124, implying a potential upside of 18.2% from current levels. Among the 30 analysts covering BSX stock, the consensus is a "Strong Buy."
BSX's strong performance can be credited to its robust product portfolio and dedicated global team. The company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more.
For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. This growth is particularly impressive when compared to the S&P 500 Index's nearly 16.6% rally over the same period. BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF, which has gained about 9% over the past year.
On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. The company reported an adjusted EPS of $0.75 for Q2, beating Wall Street's expectations of $0.72.
BSX is headquartered in Marlborough, Massachusetts, and has a market cap of $157.9 billion. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%.
It's important to note that all information and data in this article is solely for informational purposes. Readers are advised to view the article's Disclosure Policy for more information. At the time of publication, Neha Panjwani did not have positions in any of the securities mentioned in this article.
The consensus among analysts remains bullish, with 27 analysts suggesting a "Strong Buy" now, compared to 25 two months ago. This bullish sentiment is reflected in BSX's performance in 2025, where the stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis.
In conclusion, the consensus price target for BSX stock is approximately $120 to $125, reflecting confidence in the company’s recent performance and outlook. The current share price is about $106.76, indicating upside potential according to these targets.
Analysts, such as Jayson Bedford from Raymond James Financial, Inc., consistently maintain a positive outlook on Boston Scientific Corporation (BSX), with a "Buy" rating and price targets around $120 to $125. This bullish sentiment is shared by 27 analysts, a slight increase from 25 two months ago, indicating continued confidence in BSX's robust product portfolio and future growth.
Boston Scientific Corporation's current performance in the financial markets showcases its potential upside, with the consensus price target of $120 to $125 representing an 11% to 18% premium over the current share price, making it an attractive investment opportunity in the business and investing sphere.
